FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes
The FDA advisers said the pivotal approval study was too short and did not involve enough patients to characterize efficacy or safety.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news
More News: Diabetes | Diabetes Type 1 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Jardiance | Study